SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.
Details of the company’s participation are as follows:
- Cantor Fitzgerald Global Healthcare Conference 2023
- Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.
- Date and Time: Thursday, September 28th at 9:10 A.M. ET
- Location: New York, NY
Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com
- Keen’s Modern Safety Strategy Earns International ‘Groundbreaker’ Award for Excellence - September 28, 2023
- Aimfinity Investment Corp. I Announces Third Extension of the Deadline for an Initial Business Combination to October 28, 2023 - September 28, 2023
- ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – INFI - September 28, 2023
